Tumour markers are poor predictors for relapse or progression in neuroblastoma
- 1 September 2003
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (13) , 1899-1903
- https://doi.org/10.1016/s0959-8049(03)00376-9
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Follow-up in Neuroblastoma: Comparison of Metaiodobenzylguanidine and a Chimeric Anti-GD2 Antibody for Detection of Tumor Relapse and Therapy ResponseJournal of Pediatric Hematology/Oncology, 2001
- Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastomaMedical and Pediatric Oncology, 2001
- NeuroblastomaDrugs, 2000
- Neuron-Specific Enolase Evaluation in Patients with NeuroblastomaTumor Biology, 1998
- Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.Journal of Clinical Oncology, 1993
- Serum vanillylmandelic acid/homovanillic acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastomaEuropean Journal Of Cancer, 1992
- International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.Journal of Clinical Oncology, 1988
- Effect of age on homovanillic and 4-hydroxy-3-methoxymandelic acid levels in plasmaEuropean Journal of Pediatrics, 1986
- Mass fragmentographic determination of homovanillic and 4-hydroxy-3-methoxy mandelic acids in 50 μl plasmaClinica Chimica Acta; International Journal of Clinical Chemistry, 1983
- Clinical significance of catecholamine excretion levels in diagnosis and treatment of neuroblastoma.Archives of Disease in Childhood, 1975